Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients

Abstract

Intratumoral Tavo was well tolerated and led to systemic immune responses in advanced melanoma patients. While tumor regression and increased immune infiltration were observed in treated as well as untreated/distal lesions, adaptive immune resistance limited the response.